Drug
Evogliptin clinical trials
Also written DA-1229.
- studies test it
- 21
- open now
- 0
- in phase 3
- 4
- first study started
- 2009
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
21 studies that test it; most in 2020 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2016 | 4 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 4
- Phase 3
- 4
- Phase 4
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 5
Dong-A ST Co., Ltd. (12) · Dong-A Pharmaceutical Co., Ltd. (2) · Samsung Medical Center (1) · Eurofarma Laboratorios S.A. (1) · REDNVIA Co., Ltd. (1) · Seung Up Kim (1) · Kyung Hee University Hospital at Gangdong (1) · Asan Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Evogliptin is read from its arms, and is right about nine times in ten.
Testing it · 21
- A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)TerminatedPhase 2/3REDNVIA Co., Ltd.NCT05143177Written as Evogliptin
- Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVDCompletedPhase 2Dong-A ST Co., Ltd.NCT04055883Written as DA-1229
- Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 DiabetesStatus unknownPhase 4Seung Up KimNCT05473806Written as Evogliptin 5mg
- Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic ControlCompletedPhase 3Dong-A ST Co., Ltd.NCT04170998Written as Evogliptin 5mg
- The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis PatientsCompletedPhase 1Dong-A ST Co., Ltd.NCT04195919Written as Evogliptin 5mg
- Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver DiseasesCompletedPhase 4Dong-A ST Co., Ltd.NCT03910361Written as Evogliptin
- A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and DapagliflozinStatus unknownPhase 4Kyung Hee University Hospital at GangdongNCT04706637Written as Evogliptin
- A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mgStatus unknownPhase 4Dong-A ST Co., Ltd.NCT04653779Written as Evogliptin 5mg/Metformin 1000mg
- Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVDStatus unknownPhase 4Asan Medical CenterNCT04521452Written as Evogliptin
- Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal InsufficiencyCompletedPhase 2Samsung Medical CenterNCT03667300Written as Evogliptin
- Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)CompletedPhase 2Eurofarma Laboratorios S.A.NCT02689362Written as Evogliptin
- Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)CompletedPhase 4Dong-A ST Co., Ltd.NCT02974504Written as evogliptin
- Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic DysfunctionCompletedPhase 1Dong-A ST Co., Ltd.NCT02754219Written as Evogliptin
- Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mgCompletedPhase 1Dong-A ST Co., Ltd.NCT02753803Written as Evogliptin, Pioglitazone, Evogliptin+Pioglitazone
- A Clinical Trial to Investigate the Efficacy and Safety of EvogliptinCompletedPhase 3Dong-A ST Co., Ltd.NCT02946541Written as evogliptin 5mg
- Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 DiabetesCompletedPhase 3Dong-A ST Co., Ltd.NCT02949193Written as evogliptin
- Effect of Evogliptin on Bone Metabolism in HumanStatus unknownPhase 4DongGuk UniversityNCT02587975Written as Evogliptin
- PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired PatientsCompletedPhase 1Dong-A ST Co., Ltd.NCT02214693Written as DA-1229
- Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229Status unknownPhase 1Dong-A ST Co., Ltd.NCT02267902Written as DA-1229
- Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male SubjectsCompletedPhase 1Dong-A Pharmaceutical Co., Ltd.NCT01941199Written as DA-1229
See all 21 studies that test Evogliptin →
Given in every arm · 1 — Evogliptin is usual care beside what is tested
Codes
What other systems call Evogliptin · ClinicalTrials.gg INT005824
- UNII (FDA) 09118300L7EVOGLIPTINConfirmed FDA, Wikidata
- Wikidata Q25103700EvogliptinConfirmed FDA, Wikidata
- NCI Thesaurus C171769EvogliptinOne source FDA
- DrugBank DB12625One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 09118300L7 | EVOGLIPTIN | Confirmed FDA, Wikidata |
| Wikidata | Q25103700 | Evogliptin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C171769 | Evogliptin | One source FDA |
| DrugBank | DB12625 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.